Suppr超能文献

药物发现与精准医学中的偏向性信号传导

Biased signaling in drug discovery and precision medicine.

作者信息

Ji Ren-Lei, Tao Ya-Xiong

机构信息

Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, United States.

出版信息

Pharmacol Ther. 2025 Apr;268:108804. doi: 10.1016/j.pharmthera.2025.108804. Epub 2025 Feb 2.

Abstract

Receptors are crucial for converting chemical and environmental signals into cellular responses, making them prime targets in drug discovery, with about 70% of drugs targeting these receptors. Biased signaling, or functional selectivity, has revolutionized drug development by enabling precise modulation of receptor signaling pathways. This concept is more firmly established in G protein-coupled receptor and has now been applied to other receptor types, including ion channels, receptor tyrosine kinases, and nuclear receptors. Advances in structural biology have further refined our understanding of biased signaling. This targeted approach enhances therapeutic efficacy and potentially reduces side effects. Numerous biased drugs have been developed and approved as therapeutics to treat various diseases, demonstrating their significant therapeutic potential. This review provides a comprehensive overview of biased signaling in drug discovery and disease treatment, highlighting recent advancements and exploring the therapeutic potential of these innovative modulators across various diseases.

摘要

受体对于将化学和环境信号转化为细胞反应至关重要,这使其成为药物研发的主要靶点,约70%的药物都以这些受体为靶点。偏向性信号传导,即功能选择性,通过实现对受体信号通路的精确调控,彻底改变了药物研发。这一概念在G蛋白偶联受体中得到了更坚实的确立,现在已应用于其他受体类型,包括离子通道、受体酪氨酸激酶和核受体。结构生物学的进展进一步完善了我们对偏向性信号传导的理解。这种靶向方法提高了治疗效果,并有可能减少副作用。许多偏向性药物已被开发并批准作为治疗各种疾病的药物,证明了它们巨大的治疗潜力。本综述全面概述了药物研发和疾病治疗中的偏向性信号传导,突出了近期的进展,并探讨了这些创新调节剂在各种疾病中的治疗潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验